Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cisplatin
Drug ID BADD_D00474
Description Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status approved
ATC Code L01XA01
DrugBank ID DB00515
KEGG ID D00275
MeSH ID D002945
PubChem ID 5702198
TTD Drug ID D0U5HU
NDC Product Code 16729-288; 25021-253; 0143-9505; 68554-0077; 0143-9504; 68001-283; 44567-509; 50711-0001; 44567-510; 63323-103; 0703-5747; 0703-5748; 44567-530; 60505-6277; 68083-163; 44567-511; 49452-2078; 54875-0001; 67184-0010; 68083-162; 70860-206; 49812-0009; 72659-864
UNII Q20Q21Q62J
Synonyms Cisplatin | cis-Diamminedichloroplatinum(II) | Platinum Diamminodichloride | Diamminodichloride, Platinum | cis-Platinum | cis Platinum | Dichlorodiammineplatinum | cis-Diamminedichloroplatinum | cis Diamminedichloroplatinum | cis-Dichlorodiammineplatinum(II) | NSC-119875 | Platino | Platinol | Biocisplatinum | Platidiam
Chemical Information
Molecular Formula PtCl2(NH3)2
CAS Registry Number 15663-27-1
SMILES N.N.Cl[Pt]Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Injection site swelling12.07.03.018; 08.02.03.0170.000246%Not Available
Infusion site pain08.02.05.014; 12.07.05.0020.000817%Not Available
Nodule08.03.05.0020.000112%Not Available
Fluid intake reduced14.05.10.0010.000224%Not Available
Pulmonary mass22.02.07.0040.000336%Not Available
Pneumatosis intestinalis07.11.01.0430.000336%Not Available
Urine odour abnormal20.02.01.0200.000112%Not Available
Paraesthesia oral17.02.06.008; 07.05.05.0350.000112%Not Available
Pulseless electrical activity02.03.04.0200.000112%Not Available
Nail pigmentation23.02.05.0070.000112%Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.0010.000336%Not Available
Bicytopenia01.03.03.0100.000280%Not Available
Gastrointestinal toxicity12.03.01.019; 07.08.03.0060.001007%Not Available
Ventricular dysfunction02.04.02.0050.000168%Not Available
Angiopathy24.03.02.007--Not Available
Metastases to central nervous system17.02.10.013; 16.22.02.0040.000336%Not Available
Extremity necrosis24.04.03.0120.000492%Not Available
Skin toxicity23.03.03.032; 12.03.01.0200.000336%Not Available
Drug resistance08.06.01.0050.000839%Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Cranial nerve disorder17.04.01.0010.000112%Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.000560%Not Available
Embolism24.01.01.0090.000560%
Haematotoxicity12.03.01.025; 01.05.01.0070.001567%Not Available
Inflammation08.01.05.007; 10.02.01.0890.000716%Not Available
Ischaemia24.04.02.0040.000112%Not Available
Laryngeal disorder22.04.01.0010.000112%Not Available
Malnutrition14.03.02.0040.001086%Not Available
Metastatic neoplasm16.16.01.0070.000168%Not Available
Neoplasm progression16.16.02.0050.000862%Not Available
The 15th Page    First    Pre   15 16 17 18 19    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene